NCT05682001

Brief Summary

To study the molecular pathogenesis of cataract and explore possible treatments，anterior lens capsules were collected from cataract patients

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

December 6, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 12, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

January 12, 2023

Status Verified

January 1, 2023

Enrollment Period

1.9 years

First QC Date

December 6, 2022

Last Update Submit

January 3, 2023

Conditions

CataractPathogenesis

Outcome Measures

Primary Outcomes (4)

  • m6A modification of mRNAs

    Epitranscriptomic microarray analysis reveals the differential m6A modification of mRNAs in DC samples

    1 month

  • expression level of mRNAs

    the m6A microarray analyses provide data for mRNA expression levels

    1 month

  • levels of methylated mRNA

    in vitro validation of the diverse expression levels of methylated mRNA

    1 month

  • levels of RNA methyltransferase

    in vitro validation of the diverse expression levels of RNA methyltransferase

    1 month

Study Arms (3)

DC group

Anterior lens capsule tissues from DC patients

ARC group

Anterior lens capsule tissues from ARC patients

NC group

anterior lens capsules collected from three age-matched transparent crystals of cadaveric eyes

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Anterior lens capsule tissues from cataract patients with diabetes mellitus more than 10 years, patients with age related cataract, and transparent crystals of cadaveric eyes.

You may qualify if:

  • diabetic cataract
  • underwent cataract surgery

You may not qualify if:

  • Combined with other eye diseases
  • underwent other eye surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eye & ENT Hospital of Fudan University

Shanghai, Shanghai Municipality, 200031, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Anterior lens capsule tissues from cataract patients

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Study Officials

  • Jin Yang, PhD

    Eye & ENT Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Lei Cai, MD

CONTACT

13816956828clyc0318@126.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 6, 2022

First Posted

January 12, 2023

Study Start

January 1, 2022

Primary Completion

December 1, 2023

Study Completion

December 30, 2025

Last Updated

January 12, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)